vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Doximity, Inc. runs the higher net margin — 33.3% vs 1.6%, a 31.6% gap on every dollar of revenue. On growth, Doximity, Inc. posted the faster year-over-year revenue change (9.8% vs 5.0%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs -0.2%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DOCS vs PCRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $177.4M |
| Net Profit | $61.6M | $2.9M |
| Gross Margin | 89.9% | — |
| Operating Margin | 38.9% | 3.9% |
| Net Margin | 33.3% | 1.6% |
| Revenue YoY | 9.8% | 5.0% |
| Net Profit YoY | -18.1% | — |
| EPS (diluted) | $0.31 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $185.1M | $196.9M | ||
| Q3 25 | $168.5M | $179.5M | ||
| Q2 25 | $145.9M | $181.1M | ||
| Q1 25 | $138.3M | $168.9M | ||
| Q4 24 | $168.6M | $187.3M | ||
| Q3 24 | $136.8M | $168.6M | ||
| Q2 24 | $126.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $5.4M | ||
| Q2 25 | $53.3M | $-4.8M | ||
| Q1 25 | $62.5M | $4.8M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $-143.5M | ||
| Q2 24 | $41.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 89.9% | 79.5% | ||
| Q3 25 | 90.3% | 80.9% | ||
| Q2 25 | 89.2% | 77.4% | ||
| Q1 25 | 89.5% | 79.7% | ||
| Q4 24 | 91.6% | 78.7% | ||
| Q3 24 | 90.0% | 76.9% | ||
| Q2 24 | 89.3% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 38.9% | 1.2% | ||
| Q3 25 | 37.8% | 3.5% | ||
| Q2 25 | 37.4% | 4.7% | ||
| Q1 25 | 35.2% | 1.2% | ||
| Q4 24 | 47.4% | 13.2% | ||
| Q3 24 | 38.8% | -82.8% | ||
| Q2 24 | 36.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | 3.0% | ||
| Q2 25 | 36.5% | -2.7% | ||
| Q1 25 | 45.2% | 2.8% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | -85.1% | ||
| Q2 24 | 32.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.31 | $0.05 | ||
| Q3 25 | $0.31 | $0.12 | ||
| Q2 25 | $0.27 | $-0.11 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.37 | $0.38 | ||
| Q3 24 | $0.22 | $-3.11 | ||
| Q2 24 | $0.21 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $653.9M |
| Total Assets | $1.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $64.8M | $238.4M | ||
| Q3 25 | $169.2M | $246.3M | ||
| Q2 25 | $137.3M | $445.9M | ||
| Q1 25 | $209.6M | $493.6M | ||
| Q4 24 | $165.3M | $484.6M | ||
| Q3 24 | $184.2M | $453.8M | ||
| Q2 24 | $111.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $979.3M | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.0B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.0B | $778.3M | ||
| Q3 24 | $961.2M | $749.6M | ||
| Q2 24 | $913.6M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $60.9M | $43.7M | ||
| Q3 25 | $93.9M | $60.8M | ||
| Q2 25 | $62.1M | $12.0M | ||
| Q1 25 | $98.5M | $35.5M | ||
| Q4 24 | $65.2M | $33.1M | ||
| Q3 24 | $68.3M | $53.9M | ||
| Q2 24 | $41.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | 0.0% | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | 11.20× | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | 7.37× | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
